secwatch.observer — SEC 8-K summary
======================================

Issuer:     AYTU BIOPHARMA, INC (AYTU)
CIK:        0001385818
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0001437749-24-030297
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aytu BioPharma signs exclusive agreement with Lupin to commercialize Adzenys XR-ODT and Cotempla XR-ODT in Canada
--------------------------------------------------------------------------------

- Exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada for Aytu's ADHD products.
- Adzenys XR-ODT and Cotempla XR-ODT are the only extended-release orally disintegrating ADHD tablets; Health Canada approval needed.
- Aytu's ADHD prescriptions grew 16.5% over two years; Canadian stimulant market was $1.1B CAD (4.5M units) in 2023.
- Lupin will seek regulatory approvals over 18-24 months; financial terms not disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924030297/0001437749-24-030297-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1385818/000143774924030297/aytu20240723_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-030297

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer